Figure 2.

Kinetics of peripheral blood NK (CD3–/CD56+) cells (A) and CD16-dependent killing capacity of peripheral blood NK cells (B) following infusion of imgatuzumab or cetuximab. A dramatic decrease in the number of peripheral NK cells was seen with the first infusion of imgatuzumab (beginning as early as the end of the infusion) but not with cetuximab (A). NK cell numbers recovered to some extent by the time of the second infusion. The functional capacity of the remaining NK cells appeared relatively unchanged (B). BL, baseline; B-i, beginning of infusion; CD, cluster of differentiation; D1/8, day 1/8; E-i, end of infusion; NK, natural killer.